Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical Technology Enterprise Consortium, 51433 [2017-24101]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 213 / Monday, November 6, 2017 / Notices
DEPARTMENT OF JUSTICE
Antitrust Division
Pmangrum on DSK3GDR082PROD with NOTICES
Notice Pursuant to the National
Cooperative Research and Production
Act of 1993—Medical Technology
Enterprise Consortium
Notice is hereby given that, on
September 29, 2017, pursuant to Section
6(a) of the National Cooperative
Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (‘‘the Act’’),
Medical Technology Enterprise
Consortium (‘‘MTEC’’) has filed written
notifications simultaneously with the
Attorney General and the Federal Trade
Commission disclosing changes in its
membership. The notifications were
filed for the purpose of extending the
Act’s provisions limiting the recovery of
antitrust plaintiffs to actual damages
under specified circumstances.
Specifically, 2C4 Technologies, Inc.,
San Antonio, TX; Actuated Medical,
Inc., Bellefonte, PA; American Type
Culture Collection (ATCC Federal
Solutions), Manassas, VA; Amethyst
Technologies, LLC, Baltimore, MD; Anu
Life Sciences, Sunrise, FL; Arteriocyte,
Inc. d/b/a/Compass Biomedical,
Hopkinton, MA; Charles River
Analytics, Inc., Cambridge, MA;
Chimerix, Inc., Durham, NC; Cole
Engineering Services, Inc., Orlando, FL;
Corvid Technologies, Mooresville, NC;
Daxor Corporation, New York, NY;
Elemance, LLC, Clemmons, NC;
Emergent BioSolutions, Gaithersburg,
MD; Human Biomed, Inc., South
Burlington, VT; L–3 Applied
Technologies, Inc., San Diego, CA;
LifeLink Foundation, Inc., Tampa, FL;
MalarVx, Inc., Seattle, WA; Manzanita
Pharmaceuticals, Inc., Woodside, CA;
Medtronic, Minneapolis, MN; Melinta
Therapeutics, Inc., New Haven, CT;
Neuroplast BV, Maastricht,
NETHERLANDS; Platelet BioGenesis,
Inc., Boston, MA; RegeniSource LLC,
San Antonio, TX; Remedor Biomed Ltd.,
Nazareth lllit, ISRAEL; Roccor, LLC,
Longmont, CO; Soar Technology, Inc.,
Ann Arbor, MI; SynDaver Labs, Tampa,
FL; The Board of Supervisors of
Louisiana State University and
Agricultural & Mechanical College
herein represented by Louisiana State
University Health Sciences Center in
New Orleans (LSUHSC), New Orleans,
LA; The Medical College of Wisconsin,
Inc., Milwaukee, WI; The Metis
Foundation, San Antonio, TX;
University of Iowa, Iowa city, IA;
University of Maryland, College Park,
MD; Vcom3D, Inc., Orlando, FL, and
Vivacelle Bio, Inc., Chicago, IL have
been added as parties to this venture.
VerDate Sep<11>2014
14:48 Nov 03, 2017
Jkt 244001
Also, Applied Medical Device
Institute (aMDI)—Grand Valley State
University, Grand Rapids, MI; Aptus,
LLC, Clemson, SC; Ellipsis
Technologies, Inc., Greenville, SC; Johns
Hopkins University, Baltimore, MD;
Longeveron LLC, Miami, FL; Lovelace
Biomedical and Environmental
Research Institute, Albuquerque, NM;
MicroCures, Inc., Santa Cruz, CA; New
York Institute of Technology, Old
Westbury, NY; NGT–VC 2012 Limited
Partnership (NGT3), Nazareth, ISRAEL;
and Otologic Pharmaceutics Inc.,
Oklahoma City, OK, have withdrawn as
parties to this venture.
No other changes have been made in
either the membership or planned
activity of the group research project.
Membership in this group research
project remains open, and MTEC
intends to file additional written
notifications disclosing all changes in
membership.
On May 9, 2014, MTEC filed its
original notification pursuant to Section
6(a) of the Act. The Department of
Justice published a notice in the Federal
Register pursuant to Section 6(b) of the
Act on June 9, 2014 (79 FR 32999).
The last notification was filed with
the Department on June 23, 2017. A
notice was published in the Federal
Register pursuant to Section 6(b) of the
Act on August 15, 2017(82 FR 38708).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust
Division.
[FR Doc. 2017–24101 Filed 11–3–17; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
ChipRX, L.L.C., d/b/a City Center
Pharmacy; Decision and Order
On August 19, 2016, the former
Acting Administrator issued an Order to
Show Cause and Immediate Suspension
of Registration to ChipRX, L.L.C., d/b/a
City Center Pharmacy (hereinafter,
Registrant), of Hamlin, West Virginia.
The Show Cause Order proposed the
revocation of Registrant’s DEA
Certificate of Registration and the denial
of any pending application to renew or
modify its registration, on the ground
that its ‘‘continued registration is
inconsistent with the public interest.’’
Show Cause Order, at 1 (citing 21 U.S.C.
824(a)(4) and 823(f)).
As to the Agency’s jurisdiction, the
Show Cause Order alleged that
Registrant is registered as a pharmacy
with authority to dispense schedule II–
V controlled substances under
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
51433
Registration No. FC3015915, at the
registered address of 8119 Court
Avenue, Hamlin, West Virginia. Id. at 1.
The Order alleged that this registration
was due to expire on August 31, 2017.
Id.
As to the substantive grounds for the
proceeding, the Show Cause Order
alleged that Registrant is owned by
George ‘‘Chip’’ Chapman and Summer
Chapman, and that George Chapman is
Registrant’s Pharmacist-in-Charge (PIC).
Id. The Show Cause Order alleged that
on June 30, 2016, DEA executed an
Administrative Inspection Warrant
(AIW) at Registrant based on ‘‘tips that
PIC Chapman was frequently impaired
and was unlawfully removing
controlled substances from the
pharmacy.’’ Id. at 2. The Order then
alleged that during the inspection, DEA
personnel interviewed PIC Chapman
and other pharmacy employees. Id.
With respect to the interview of PIC
Chapman, the Show Cause Order
alleged that he made various material
false statements to the Investigators. Id.
These included minimizing the quantity
of oxycodone and hydrocodone that had
been lost ‘‘in the last year,’’ stating that
he had failed to reported all but one of
the instances in which these drugs were
‘‘lost’’ because they were ‘‘‘not
significant’ losses,’’ by denying that he
knew ‘‘anything further about the nature
of the pharmacy’s losses’’ while
‘‘claim[ing] that he was not abusing
prescriptions drugs,’’ and stating ‘‘that
many of his per diem or fill-in
pharmacists were previous drug
abusers.’’ Id.
The Show Cause Order then alleged
that in a subsequent interview
conducted on July 22, 2016, Chapman
‘‘admitted that during the past year, he
diverted oxycodone or hydrocodone
pills equivalent to ‘200–300 mg every
day,’ a total of approximately 25,000
pills.’’ Id. at 3. The Order also alleged
that ‘‘Chapman admitted that he
routinely falsified inventory records’’
and that he ‘‘shredded invoice and
supplier records, including DEA 222
forms and electronic Controlled
Substances Ordering System (‘CSOS’)
records.’’ Id. The Order further alleged
that ‘‘Chapman admitted that he had
relapsed,’’ and told ‘‘DEA [I]nvestigators
that he ‘couldn’t wait’ for’’ the
expiration of the Memorandum of
Agreement (MOA) which he had
previously entered into with the Agency
‘‘so he could begin diverting . . . drugs
to feed his addiction.’’ Id. The Order
then alleged that Chapman admitted to
E:\FR\FM\06NON1.SGM
06NON1
]]>Agencies
[Federal Register Volume 82, Number 213 (Monday, November 6, 2017)]
[Notices]
[Page 51433]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24101]
[[Page 51433]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Medical Technology Enterprise Consortium
Notice is hereby given that, on September 29, 2017, pursuant to
Section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), Medical Technology
Enterprise Consortium (``MTEC'') has filed written notifications
simultaneously with the Attorney General and the Federal Trade
Commission disclosing changes in its membership. The notifications were
filed for the purpose of extending the Act's provisions limiting the
recovery of antitrust plaintiffs to actual damages under specified
circumstances. Specifically, 2C4 Technologies, Inc., San Antonio, TX;
Actuated Medical, Inc., Bellefonte, PA; American Type Culture
Collection (ATCC Federal Solutions), Manassas, VA; Amethyst
Technologies, LLC, Baltimore, MD; Anu Life Sciences, Sunrise, FL;
Arteriocyte, Inc. d/b/a/Compass Biomedical, Hopkinton, MA; Charles
River Analytics, Inc., Cambridge, MA; Chimerix, Inc., Durham, NC; Cole
Engineering Services, Inc., Orlando, FL; Corvid Technologies,
Mooresville, NC; Daxor Corporation, New York, NY; Elemance, LLC,
Clemmons, NC; Emergent BioSolutions, Gaithersburg, MD; Human Biomed,
Inc., South Burlington, VT; L-3 Applied Technologies, Inc., San Diego,
CA; LifeLink Foundation, Inc., Tampa, FL; MalarVx, Inc., Seattle, WA;
Manzanita Pharmaceuticals, Inc., Woodside, CA; Medtronic, Minneapolis,
MN; Melinta Therapeutics, Inc., New Haven, CT; Neuroplast BV,
Maastricht, NETHERLANDS; Platelet BioGenesis, Inc., Boston, MA;
RegeniSource LLC, San Antonio, TX; Remedor Biomed Ltd., Nazareth lllit,
ISRAEL; Roccor, LLC, Longmont, CO; Soar Technology, Inc., Ann Arbor,
MI; SynDaver Labs, Tampa, FL; The Board of Supervisors of Louisiana
State University and Agricultural & Mechanical College herein
represented by Louisiana State University Health Sciences Center in New
Orleans (LSUHSC), New Orleans, LA; The Medical College of Wisconsin,
Inc., Milwaukee, WI; The Metis Foundation, San Antonio, TX; University
of Iowa, Iowa city, IA; University of Maryland, College Park, MD;
Vcom3D, Inc., Orlando, FL, and Vivacelle Bio, Inc., Chicago, IL have
been added as parties to this venture.
Also, Applied Medical Device Institute (aMDI)--Grand Valley State
University, Grand Rapids, MI; Aptus, LLC, Clemson, SC; Ellipsis
Technologies, Inc., Greenville, SC; Johns Hopkins University,
Baltimore, MD; Longeveron LLC, Miami, FL; Lovelace Biomedical and
Environmental Research Institute, Albuquerque, NM; MicroCures, Inc.,
Santa Cruz, CA; New York Institute of Technology, Old Westbury, NY;
NGT-VC 2012 Limited Partnership (NGT3), Nazareth, ISRAEL; and Otologic
Pharmaceutics Inc., Oklahoma City, OK, have withdrawn as parties to
this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and MTEC intends to file additional
written notifications disclosing all changes in membership.
On May 9, 2014, MTEC filed its original notification pursuant to
Section 6(a) of the Act. The Department of Justice published a notice
in the Federal Register pursuant to Section 6(b) of the Act on June 9,
2014 (79 FR 32999).
The last notification was filed with the Department on June 23,
2017. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on August 15, 2017(82 FR 38708).
Patricia A. Brink,
Director of Civil Enforcement, Antitrust Division.
[FR Doc. 2017-24101 Filed 11-3-17; 8:45 am]
BILLING CODE P
